Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sumner

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Addiction Medicine|February 27, 2016
Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual FilmErik W Gunderson, Michael Sumner
International Wound Journal|March 20, 2013
A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcersKeith Harding, Michael Sumner, Matthew Cardinal
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 26, 2018
Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteersMartin Jönsson, Gill Mundin, Michael Sumner
Clinical Therapeutics|September 29, 2015
Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trialErik W Gunderson, Peter Hjelmström, Michael Sumner, et al.
Journal of Addiction Medicine|March 30, 2017
Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension StudyKent Hoffman, Marvin L Peyton, Michael Sumner
Hospital Practice (1995)|July 23, 2016
Compartment syndrome of the deltoid: a case report of a common presentation in a rare locationAndrew Harrison, Michael Sumner, Jeffrey Sobecki, et al.
Digestive Diseases and Sciences|September 1, 2011
Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions databaseSunanda V Kane, Michael Sumner, Dory Solomon, et al.
Journal of Addictive Diseases|June 9, 2016
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trialLynn Webster, Peter Hjelmström, Michael Sumner, et al.
Expert Opinion on Pharmacotherapy|May 23, 2007
Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitorsJennifer M Stephens, Ashish V Joshi, Michael Sumner, et al.
Plos One|September 14, 2017
Bio-physical characterisation of polynyas as a key foraging habitat for juvenile male southern elephant seals (Mirounga leonina) in Prydz Bay, East AntarcticaVeda Malpress, Sophie Bestley, Stuart Corney, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Addiction Medicine|February 27, 2016
Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual FilmErik W Gunderson, Michael Sumner
International Wound Journal|March 20, 2013
A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcersKeith Harding, Michael Sumner, Matthew Cardinal
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 26, 2018
Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteersMartin Jönsson, Gill Mundin, Michael Sumner
Clinical Therapeutics|September 29, 2015
Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trialErik W Gunderson, Peter Hjelmström, Michael Sumner, et al.
Journal of Addiction Medicine|March 30, 2017
Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension StudyKent Hoffman, Marvin L Peyton, Michael Sumner
Hospital Practice (1995)|July 23, 2016
Compartment syndrome of the deltoid: a case report of a common presentation in a rare locationAndrew Harrison, Michael Sumner, Jeffrey Sobecki, et al.
Digestive Diseases and Sciences|September 1, 2011
Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions databaseSunanda V Kane, Michael Sumner, Dory Solomon, et al.
Journal of Addictive Diseases|June 9, 2016
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trialLynn Webster, Peter Hjelmström, Michael Sumner, et al.
Expert Opinion on Pharmacotherapy|May 23, 2007
Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitorsJennifer M Stephens, Ashish V Joshi, Michael Sumner, et al.
Plos One|September 14, 2017
Bio-physical characterisation of polynyas as a key foraging habitat for juvenile male southern elephant seals (Mirounga leonina) in Prydz Bay, East AntarcticaVeda Malpress, Sophie Bestley, Stuart Corney, et al.
Pageof 3